Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11567090 | 0.89 | KDM4E (0.36) | TSHRKDM4EKMT2AALDH1A1GLA | |
| SCHEMBL3075239 | 0.87 | SMN1; SMN2 (0.34) | KDM4EKMT2AALDH1A1CYP2C19TDP1 | |
| SCHEMBL2806331 | 0.84 | SMN1; SMN2 (0.40) | ALDH1A1TDP1SMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL16973600 | 0.82 | L3MBTL1 (0.38) | TSHRKDM4EKMT2AALDH1A1CYP2D6 | |
| SCHEMBL5369031 | 0.81 | F2 (0.38) | KDM4EALDH1A1GLATDP1L3MBTL1 | |
| SCHEMBL11566227 | 0.79 | TSHR (0.35) | TSHRKDM4EKMT2AALDH1A1GLA | |
| SCHEMBL188652 | 0.79 | CYP1A2 (0.47) | KDM4EALDH1A1CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL10272925 | 0.79 | CYP2D6 (0.54) | TSHRKDM4EKMT2AALDH1A1GLA | |
| SCHEMBL3082367 | 0.77 | FDPS (0.33) | TSHRKMT2AALDH1A1CYP2C19DRD4 | |
| SCHEMBL10458094 | 0.76 | ALDH1A1 (0.38) | KDM4EKMT2AALDH1A1GLATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101326180-A | Piperazine derivative renin inhibitors | NOVARTIS AG (CH) | 2008-12-17 | — | — | CN | claimed |
| US-20080242662-A1 | Organic Compounds | NIHONYANAGI ATSUKO | 2008-10-02 | — | — | US | claimed |
| EP-1915366-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | Novartis AG (CH) | 2008-04-30 | — | — | EP | claimed |
| WO-2006128659-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS. | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | claimed |
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| CN-101326180-A | Piperazine derivative renin inhibitors | NOVARTIS AG (CH) | 2008-12-17 | — | — | CN | disclosed |
| US-20080242662-A1 | Organic Compounds | NIHONYANAGI ATSUKO | 2008-10-02 | — | — | US | disclosed |
| EP-1915366-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | Novartis AG (CH) | 2008-04-30 | — | — | EP | disclosed |
| EP-1836163-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | Novartis AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006128659-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS. | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | TSHR 2000/4885KDM4E 1562/4885KMT2A 3722/4885 |
| US-20080242662-A1 | Organic Compounds | REN, ACE, ECE1 | TSHR 2291/4885KDM4E 1853/4885KMT2A 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.